01440125_Does Synbiotic Supplementation Improve Clinical Outcomes in Critically Ill Patients HN-

Introduction: Critical illness is characterized by loss of commensal flora and overgrowth of potentially pathogenic bacteria. Gut microbiota modulation through synbiotics may restore balance and have positive effects on the function of immune system, gastrointestinal and other organs. The purpose of this study was to evaluate the effect of synbiotic supplementation in critically ill patients on clinical outcomes.Methods: Critically ill patients receiving enteral nutrition therapy were included in this randomized controlled study. Patients receiving Lactocare (ZistTakhmir) capsule twice a day for a maximum of 14 days were compared with the identical placebo receiving group (20 subjects in each group). The Acute Physiology and Chronic Health (APACHE-П) and Sequential Organ Failure Assessment (SOFA) scores were recorded on days 1, 7 and 14. Length of stay (LOS) in hospital and intensive care unit (ICU) and 28-day mortality were also recorded. Data were analyzed via SPSS statistical software. Statistical significance was set at p< 0.05.Results: Overall, 38 patients (mean age 42.82 years) completed at least four days of intervention (mean 10.29 days). On day 7, APACHE-П and SOFA scores were significantly lower in the synbiotic group (18.90±5.36 vs. 19.81±3.40; p= 0.02 and 7.1±2.37 vs. 8.27±2.53; p= 0.03, respectively), while on day 1 and 14 no significant difference was observed. ICU and hospital LOS, and 28-day mortality were similar in both groups.Conclusion: Synbiotic supplementation can reduce the level of acuity and mortality risk through the first week of intervention but it has no effect on stay duration or 28-day mortality.

کلیدواژه ها:

critical care ، length of stay ، mortality ، synbiotics